Clinical trial • Phase III • Psychiatry
Psilocybin for Major depressive disorder|Anhedonia
Phase III trial of Psilocybin for Major depressive disorder|Anhedonia. None/Not specified-controlled. 85 participants.
Overview
- Trial Therapeutic Area
- Psychiatry
- Trial Disease
- Major depressive disorder|Anhedonia
- Trial Stage
- Phase III
Key dates
- Initial CTIS Submission Date
- 18-04-2024
- First CTIS Authorization Date
- 05-08-2024
Trial design
None/Not specified-controlled Phase III trial across 1 site in Austria.
- Comparator
- None/Not specified
- Target Sample Size
- 85
Recruitment
- Planned Sample Size
- 85
- Recruitment Window Months
- 41
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 85
Austria
- Earliest CTIS Part Ii Submission Date
- 01-07-2024
- Latest Decision Or Authorization Date
- 05-08-2024
- Processing Time Days
- 35
- Number Of Sites
- 1
- Number Of Participants
- 85
Sites
- Site Name
- Medical University of Vienna
- Department Name
- Division of General Psychiatry
- Principal Investigator Name
- Marie Spies
- Principal Investigator Email
- marie.spies@meduniwien.ac.at
- Contact Person Name
- Marie Spies
- Contact Person Email
- marie.spies@meduniwien.ac.at
Sponsor
Primary sponsor
- Full Name
- Medical University of Vienna
- Organisation Type
- Educational Institution
- Country Of Registered Address
- Austria
Investigational products
- Investigational Product Name
- Psilocybin
- Active Substance
- Psilocybin
- Modality
- Small molecule
Related trials
Other published trials that may interest you.